Palmetto Pharmaceuticals
Founded Year
1998Stage
Series E - II | AliveTotal Raised
$3.98MValuation
$0000Last Raised
$630K | 18 yrs agoAbout Palmetto Pharmaceuticals
Palmetto Pharmaceuticals (formerly eNOS Pharmaceuticals) has developed products that improve and restore blood flow and to reduce triglycerides through up-regulation of endothelial nitric oxide synthase (eNOS) enzyme.�The company's first drug candidate, L-arginine Sustained Release for the management of hypertriglyceridaemia, is in clinical trials in Germany.
Loading...
Loading...
Palmetto Pharmaceuticals Patents
Palmetto Pharmaceuticals has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/22/2012 | 1/20/2015 | Implants (medicine), Lactones, Statins, Diabetes, Vascular diseases | Grant |
Application Date | 3/22/2012 |
|---|---|
Grant Date | 1/20/2015 |
Title | |
Related Topics | Implants (medicine), Lactones, Statins, Diabetes, Vascular diseases |
Status | Grant |
Palmetto Pharmaceuticals Frequently Asked Questions (FAQ)
When was Palmetto Pharmaceuticals founded?
Palmetto Pharmaceuticals was founded in 1998.
Where is Palmetto Pharmaceuticals's headquarters?
Palmetto Pharmaceuticals's headquarters is located at 7 Coach Road, Lexington.
What is Palmetto Pharmaceuticals's latest funding round?
Palmetto Pharmaceuticals's latest funding round is Series E - II.
How much did Palmetto Pharmaceuticals raise?
Palmetto Pharmaceuticals raised a total of $3.98M.
Who are the investors of Palmetto Pharmaceuticals?
Investors of Palmetto Pharmaceuticals include Polaris Partners, EW Healthcare Partners and Elan International.
Who are Palmetto Pharmaceuticals's competitors?
Competitors of Palmetto Pharmaceuticals include United Biomedical, OncoMed Pharmaceuticals, Xhale, Neuraltus Pharmaceuticals, Protez Pharmaceuticals and 7 more.
Loading...
Compare Palmetto Pharmaceuticals to Competitors
Amulet Pharmaceuticals is a development stage medical device and therapeudics company where patented NORTECH „ technology aims to provide predictable and targeted time release of Nitric Oxide in the body.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
Banyan Biomarkers is a company focused on the discovery, validation, and commercialization of biochemical markers in the healthcare sector. The company's main service is the development of a blood test that aids in the evaluation of concussions, potentially eliminating the need for CT scans in patients with suspected mild traumatic brain injury. The company primarily serves the healthcare industry, particularly in the area of traumatic brain injury diagnosis. It was founded in 2013 and is based in San Diego, California.
Loading...